背景:本系统综述旨在确定流行病学概况,病因和危险因素,预防,诊断,治疗,成本效益,生存,以及与摩洛哥宫颈癌相关的生活质量。
方法:本研究是根据系统评价和荟萃分析的首选报告项目的建议进行的。\"PubMed,ScienceDirect,Springer,使用了WebofScience数据库,谷歌学者的灰色文献也是如此。审查方案已在PROSPERO寄存器(CRD42021235241)中注册。
结果:选择了50项研究。平均年龄为49.31±6.3岁。HPV感染率从13.30%到76%不等,艾滋病毒呈阳性的女性达到高峰。父母对HPV疫苗的可接受性(35%和82%)高于青少年(16.9%至46.6%)。对疫苗的了解及其价格是父母接受疫苗的两个关键因素。本系统评价强调,很少有合格的妇女(不超过11%)参加宫颈癌筛查计划。摩洛哥妇女对宫颈癌筛查的知识和意识水平较低,对他们使用这种筛查工具产生负面影响,从未接受过宫颈癌筛查的女性比例很高(平均76.32%±17.21)。治疗是全球护理预算中最重要的组成部分(95.87%),每年的费用为13,027,609美元。5年总生存率从41.3%到73.6%,早期诊断的患者生存率较高(I期为77.3-85%)。最后,在接受近距离放射治疗且缺乏社会支持的晚期肿瘤女性中,生活质量较低.
结论:需要进一步调查的对象包括摩洛哥妇女的知识,态度,和意识,尤其是那些患宫颈癌的高危人群,以及它对他们生活质量和生存的影响。
BACKGROUND: This systematic
review aims to determine the epidemiological profile, etiology and risk factors, prevention, diagnosis, treatment, cost-effectiveness, survival, and quality of life related to cervical cancer in Morocco.
METHODS: This study was conducted according to the recommendations of the \"preferred reporting items for systematic reviews and meta-analysis.\" The PubMed, ScienceDirect, Springer, Web of Science data bases were used, as was Google Scholar for the grey literature. The
review protocol was registered in the PROSPERO register (CRD42021235241).
RESULTS: Fifty studies were selected. The mean age was 49.31 ±6.3 years. HPV infection prevalence ranged from 13.30% to 76%, with a peak in HIV-positive women. Acceptability of the HPV vaccine was higher among parents (35% and 82%) than among adolescents (16.9% to 46.6%). Knowledge of the vaccine and its price are two key factors related to vaccine acceptability among parents. This systematic
review highlights that the fact that few eligible women (not more than 11%) were participating in the cervical cancer screening program. Moroccan women\'s level of knowledge and awareness regarding cervical cancer screening was low, negatively impacting their use of such screening tools, as illustrated by the high percentage (mean 76.32% ± 17.21) of women who had never been screened for cervical cancer. Treatment was the most significant component of the global care budget (95.87%), with an annual cost of $13,027,609. Five-year overall survival ranged from 41.3% to 73.6%, with higher survival rates for patients diagnosed at an earlier stage (77.3-85% for stage I). Lastly, low quality of life was observed in women with tumors at an advanced stage who had received brachytherapy and lacked social support.
CONCLUSIONS: Subjects that require further investigation include Moroccan women\'s knowledge, attitudes, and awareness, especially among those at high risk of developing cervical cancer, and its impact on their quality of life and survival.